Daniel Lenihan

A new computer algorithm developed at Vanderbilt could save billions of dollars in health care costs by identifying patients at risk for readmission after being hospitalized for heart failure. Read More

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression. Read More

Vanderbilt University Medical Center is hosting the first Global Cardio-Oncology Summit on Oct. 15-16, at the Hilton Nashville. The summit models a leading edge, interdisciplinary approach to cardio-oncology. Read More

Vanderbilt is embarking on an observational study to define and understand how a promising treatment for multiple myeloma affects the heart. Read More

The Vanderbilt Cardio-Oncology program has fostered a collaborative relationship combining the expertise of cardiologists and oncologists to understand effects of cancer therapy on the heart. Read More

The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States. Read More

Vanderbilt University Medical Center and Acorda Therapeutics Inc. released findings from a Phase 1 clinical trial of glial growth factor 2 (GGF2) last week at the American College of Cardiology Annual Scientific Session in San Francisco. Read More

A new implantable device currently being studied gives heart failure patients the ability to monitor their heart and take action when their condition begins to worsen. Read More